Protective nature of low molecular weight chitosan in a chitosan-Amphotericin B nanocomplex - A physicochemical study

Chitosan, a biopolymer of immense potential, has been well-explored over the past decade in the biomedical field. Despite its numerous biological properties like anti-microbial, anti-inflammatory, anti-diabetic etc., limited studies have been conducted on its ability to protect therapeutic molecules in nano-formulations. Amphotericin B (AMP) is one such therapeutic molecule which requires protection as it possesses inherent limitations of poor water-solubility, susceptibility to oxidation- and/or light-induced degradation etc. Although AMP formulations have been quite successful in treating chronic fungal infections, their high cost, prolonged nature of therapy and instability over longer durations has necessitated the development of alternative carriers. In the present study, a stable nanoparticulate formulation was successfully prepared using low molecular weight chitosan and the anti-fungal agent AMP and this was found to offer protection to the labile AMP. The developed nanocomplexes could prevent degradation of AMP up to six months, in solution form, unlike the native drug which degraded in <24 h. Antifungal studies of the developed nanocomplexes revealed a surface charge-dependent antifungal activity. Furthermore, the nanocomplexes did not affect the viability of mammalian cells and showed excellent intracellular uptake and retention, and hence suggested potential of the nanocomplexes in alleviating systemic fungal infections.